Apellis Pharma

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apellis Pharma reports strong Q1 revenue, eyes U.S. expansion

Apellis Pharma's Q1 2023 performance showcased strong revenue from SYFOVRE and EMPAVELI, with positive feedback and demand in the market.
While facing challenges like safety concerns and European commercialization, the company is focused on expanding market reach and driving awareness.
Opportunities lie in making SYFOVRE widely available, promoting patient education, and potential approval in Europe for further growth.

Apellis Pharma reports robust Q2 sales amidst safety event challenges

Apellis Pharma's Q2 performance highlighted strong sales, positive product efficacy, and proactive response to safety events
Despite challenges with rare safety events, the company's strengths in product credibility, manufacturing quality, and market acceptance shine through
Opportunities lie in enhancing physician education, exploring financing options, and leveraging positive efficacy evolution for market growth
Overall, Apellis Pharma's strategic measures position it well to navigate challenges, capitalize on opportunities, and maintain market confidence

Apellis Pharma reports mixed Q3 results, eyes European expansion

Apellis Pharma's Q3 performance showed strong revenue from key products but also highlighted the need for cost-saving measures. The company's focus on global expansion and product launches in Europe presents growth opportunities amidst market challenges.

Apellis Pharma reports strong Q4 earnings amidst market challenges

Apellis Pharma delivered strong financial results in Q4 2023, driven by the success of SYFOVRE and EMPAVELI in the U.S., while navigating challenges in the EU market and competitive landscape.
The company's strategic focus on patient access, market leadership, and R&D advancement positions it for continued growth and innovation in precision medicine, supported by robust engagement with medical communities.
Opportunities lie in expanding market share through bilateral treatments, advancing pipeline programs, and leveraging compliance and real-world data to strengthen Apellis Pharma's position as a leading provider of GA therapies.
Addressing challenges such as market competition, regulatory processes, and financial performance will be crucial for Apellis Pharma to sustain growth, optimize revenue, and drive profitability in the future.

Apellis Pharma reports robust Q1 performance and eyes expansion

Apellis Pharma (APLS) showcased strong financial performance and product success in Q1 2024, with plans for expansion and upcoming study data.
Despite challenges like a negative CHMP opinion and safety concerns, opportunities in education, expansion, and market penetration are on the horizon.
The company's commitment to shareholder value, financial stability, and milestone achievements sets a positive outlook for the future.

Apellis Pharma reports robust Q2 earnings, eyes market expansion

Apellis Pharma's Q2 performance reflects strong revenue growth and market leadership, supported by successful product sales and strategic initiatives.
While facing competition and challenges in market share retention, the company's focus on expansion and financial strength bode well for future growth.
Opportunities in new indications, market expansion, and pipeline development position Apellis Pharma for continued value creation for patients and shareholders.

Apellis Pharma reports robust Q3 performance amidst market challenges

Apellis Pharma's Q3 performance reflects strong demand for SYFOVRE and strategic initiatives to drive market share.
While facing challenges such as gross to net adjustments and market dynamics, the company remains optimistic about future growth opportunities.
By leveraging strengths in product efficacy and real-world data, Apellis Pharma aims to expand globally and enhance profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.

Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails

WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral sclerosis (ALS) did not meet its primary endpoint of the Combined Assessment of Function and Survival (CAFS) rank score at Week 52. The study also did not meet key secondary efficacy endpoints. Systemic pegcetacoplan was well tolerated in the study, and the data were consistent with the established safety profile.

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

Pipeline & Trials: Apellis Pharmaceuticals stands out with its C3 inhibitor, pegcetacoplan (Syfovre), offering novel treatment options for PNH and GA, with positive Phase III trial results. Treatment Impact: Syfovre is the first approved treatment for GA, slowing disease progression, while in PNH, it effectively addresses the disease's root cause.

Apellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition Space

Madrigal Pharmaceuticals

Sarepta Therapeutics

The Federal Trade Commission is suing to block the proposed merger between Amgen and Horizon Therapeutics. This adverse regulatory action rippled out across the small- and mid-cap biotech landscape today.

Why These 3 Nasdaq Stocks Buckled Today

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations and Strategic Finance Dr. Cedric Francois - Co-Founder and CEO Adam Townsend - Chief Commercial Officer Dr. Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Jon Miller - Evercore Tazeen Ahmad - BofA Anupam Rama - JPMorgan Colleen Kusy - Baird Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Justin Kim - Oppenheimer Derek Archila - Wells Fargo Eliana Merle - UBS Annabel Samimy - Stifel Joseph Stringer - Needham & Company Douglas Tsao - H.C. Wainwright Operator Good day and thank you for standing-by.

Apellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call Transcript

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.

Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth

Apellis' new eye drug, Syfovre, crushed expectations in its first quarter post launch, putting APLS stock on track to open at a record high. The post Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views appeared first on Investor's Business Daily.

Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business highlights.

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

Apellis Pharmaceuticals, a commercial-stage biopharmaceutical company, is making significant strides with Syfovre, the first and only FDA-approved treatment for geographic atrophy (GA), a condition affecting millions globally. The company's strong financial position, bolstered by a $402.5 million public offering and significant cash reserves, supports its market leadership and future growth prospects.

Apellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric Bio

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 3:40 p.m. PT.

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

TG Therapeutics

Viking Therapeutics

Biotech stocks were fairly volatile today, thanks to another buyout and a spate of earnings reports. Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics were among the most volatile in the space.

Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

WALTHAM, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2023 financial results on Thursday, May 4, 2023, at 4:30 p.m. ET.

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

WALTHAM, Mass., April 23, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the 24-month, Phase 3 OAKS and DERBY studies evaluating SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analyses were reported during oral presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place April 23-27 in New Orleans.

Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy

WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has received validation of its marketing applications by regulatory authorities in Canada, Australia, the United Kingdom, and Switzerland for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Decisions by local regulatory authorities in these countries are expected in the first half of 2024.

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

Alnylam Pharmaceuticals

argenx

Ascendis Pharma

BioMarin Pharmaceutical

Amicus Therapeutics

Horizon Pharma

United Therapeutics

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

These Are the Top 10 Holdings of Avoro Capital Advisors

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won't Wait™ Campaign

Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.

Apellis (APLS) Stock Up 50% in Three Months: Here's Why?

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?

BridgeBio Pharma Inc

Growth stocks have been under heavy pressure over the past year. A handful of biotech companies have defied this broader downturn, however.

2 Best Growth Stocks to Buy in April

Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.

Apellis (APLS) Kindles Acquisition Interest Per Bloomberg

Apellis Pharmaceuticals received FDA approval for Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration. Over 1 million people in the US and 5 million worldwide are affected by GA, providing a significant market opportunity for Apellis.

Apellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy Market

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last Earnings Report?

Amylyx Pharmaceuticals

Axsome Therapeutics

Cogint

CTI BioPharma

IVERIC bio Inc

Mirati Therapeutics

Reata Pharmaceuticals

Seagen

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

These Are the Top 10 Holdings of David Kim

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including the exercise in full by the underwriters of their option to purchase an additional 833,333 shares. The exercise of the option to purchase additional shares increased the amount of gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by Apellis, to approximately $402.5 million.

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

News for Apellis Pharma Stock (APLS)